B2M and metastatic neoplasm: The mutation profile of metastatic lesions resembles that of primary lesions in each patient, but a new/second mutation in beta-2 microglobulin (B2M) gene was identified in the metastatic tumor of respective patients [24], suggesting that B2M mutations may contribute to secondary resistance to ICIs.